- Zentek Ltd.'s wholly owned subsidiary, Albany Graphite Corp. (AGC), announced that additional material characterization tests confirm its Albany graphite meets stringent nuclear specifications, indicating its suitability for the nuclear energy industry.  **[1904501_0001062993-25-015932_exhibit99-1.htm:0]** 
- The Albany graphite achieved an **ultra-high 5N+ purity level (99.9992 wt.% C)** and an Equivalent Boron Concentration (EBC) of **2.60 ppm**, which is below the nuclear industry's 3 ppm specification.  **[1904501_0001062993-25-015932_exhibit99-1.htm:0]** 
- Other critical tests, including Air Jet Sub-Sieve Analyzer Yield, Compressibility, Four-Point Resistivity, and Coefficient of Friction, also met or exceeded industry standards for nuclear applications.  **[1904501_0001062993-25-015932_exhibit99-1.htm:0]** **[1904501_0001062993-25-015932_exhibit99-1.htm:1]** 
- The next step involves producing near-net-shaped graphite bricks to further confirm nuclear industry specifications.  **[1904501_0001062993-25-015932_exhibit99-1.htm:1]**

Zentek Subsidiary Albany Graphite Corp. Confirms Nuclear Suitability of Graphite

- **Zentek announced a CEO transition**, with **Wendy Ford appointed Interim CEO** following Greg Fenton's resignation, and a search for a new CEO is underway.  **[1904501_0001062993-25-015771_exhibit99-1.htm:0]** 
- The company provided updates on **ZenGUARD™ Enhanced Air Filters**, highlighting **42% infectious aerosol removal efficiency** in Canada  **[1904501_0001062993-25-015771_exhibit99-1.htm:0]** , eligibility for federal procurement  **[1904501_0001062993-25-015771_exhibit99-1.htm:0]** , and active engagement with partners for **international market expansion** in the US, Middle East, India, and South America.  **[1904501_0001062993-25-015771_exhibit99-1.htm:1]** **[1904501_0001062993-25-015771_exhibit99-1.htm:2]** 
- **Albany Graphite Corp. achieved a major milestone**, purifying its graphite to **5N (99.9992%) purity** with an **Equivalent Boron Concentration of 2.60 ppm**, meeting the nuclear industry's threshold for nuclear-grade material.  **[1904501_0001062993-25-015771_exhibit99-1.htm:2]** 
- **Triera Biosciences reported encouraging preliminary _in vivo_ test results** for its multivalent aptamer lead candidate against A(H1N1) pdm09, showing **5x greater survival rates** and **80% less weight loss** in treated animals.  **[1904501_0001062993-25-015771_exhibit99-1.htm:3]**

Zentek Provides Corporate Update, Announces Interim CEO, and Key Product Milestones

- **Zentek Ltd.** has completed the first *in vivo* tests for its lead influenza countermeasure candidate against H1N1 seasonal influenza, developed using multivalent aptamer technology.  **[1904501_0001062993-25-015711_exhibit99-1.htm:0]** 
- Preliminary results from animal model testing demonstrated **substantially improved clinical scores**, **5x greater survival rates**, and **80% less weight loss** 5 days post-infection compared to the control group.  **[1904501_0001062993-25-015711_exhibit99-1.htm:0]** 
- This development is part of a **$1.1 million** Innovative Solutions Canada Testing Stream contract, with further comprehensive testing against H1N1 and H5N1 scheduled to begin shortly.  **[1904501_0001062993-25-015711_exhibit99-1.htm:0]** 
- The aptamer countermeasure, licensed through Zentek's subsidiary Triera Biosciences Ltd., shows potential for both seasonal and pandemic influenza applications.  **[1904501_0001062993-25-015711_exhibit99-1.htm:0]** **[1904501_0001062993-25-015711_exhibit99-1.htm:1]**

Zentek (ZTEK)